

# Clinical trials of ACE inhibitors

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 hypertension

| Trial  | Treatments  | Patients   | Trials design and methods                                      |
|--|---|--|--|
| <b>ACE inhibitors vs placebo</b>   |   |  |  |
| <b>HOPE (diabetic subgroup), 2000</b><br>n=1808/1759<br>follow-up: 4.5 years | ramipril 10 mg once per day orally<br>versus<br>placebo | patients with diabetes (sub group), aged 55 years or older, who had a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical proteinuria, heart failure, or low ejection fraction | Factorial plan<br>double-blind<br>North, South america, Europe |

More details and results :

- anti hypertensive agents for hypertension in diabetic patients at <http://www.trialresultscenter.org/go-Q10>

## References

### **HOPE (diabetic subgroup), 2000:**

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9 [[10675071](#)]

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53 [[10639539](#)]

## 2 diabetes type 2

| Trial  | Treatments  | Patients   | Trials design and methods                                      |
|--|---|--|--|
| <b>ACE inhibitors vs placebo</b>   |   |  |  |
| <b>HOPE (diabetic subgroup), 2000</b><br>n=1808/1759<br>follow-up: 4.5 years | ramipril 10 mg once per day orally<br>versus<br>placebo | patients with diabetes (sub group), aged 55 years or older, who had a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical proteinuria, heart failure, or low ejection fraction | Factorial plan<br>double-blind<br>North, South america, Europe |

More details and results :

- anti hypertensive agents for diabetes type 2 in patients with hypertension at <http://www.trialresultscenter.org/go-Q83>
- anti hypertensive agents for diabetes type 2 in patients with or without hypertension at <http://www.trialresultscenter.org/go-Q414>
- angiotensin renin system blockade for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q438>

## References

### **HOPE (diabetic subgroup), 2000:**

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet* 2000;355:253-9 [[10675071](#)]

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:145-53 [[10639539](#)]